| Literature DB >> 33552178 |
Dawn M Emerson1, Stephen Cl Chen2, Melani R Kelly1, Bryant Parnell3, Toni M Torres-McGehee3.
Abstract
BACKGROUND: Because of their anti-pyretic effects, some individuals prophylactically use non-steroidal anti-inflammatory drugs (NSAIDs) to blunt core temperature (Tc) increases during exercise, thus, potentially improving performance by preventing hyperthermia and/or exertional heat illness. However, NSAIDs induce gastrointestinal damage, alter renal function, and decrease cardiovascular function, which could compromise thermoregulation and increase Tc. The aim of this systematic review was to evaluate the effects of NSAIDs on Tc in exercising, adult humans.Entities:
Keywords: Anti-pyretic; Cyclooxygenase inhibitor; Heat illness; Physical activity; Thermoregulation
Year: 2021 PMID: 33552178 PMCID: PMC7829260 DOI: 10.1016/j.jesf.2020.12.003
Source DB: PubMed Journal: J Exerc Sci Fit ISSN: 1728-869X Impact factor: 3.103
Fig. 1PRISMA flow chart illustrating the different phases of the literature search and study selection.
Physiotherapy evidence database (PEDro) scale scores of critically reviewed articles.
| Bass & Jacobson | Bradford et al. | Bruning et al. | de Meersman | Downey & Darling | Emerson et al. | Farquhar & Kenney | Farquhar et al. | |
|---|---|---|---|---|---|---|---|---|
| Eligibility criteria specified (no points) | ||||||||
Subjects were allocated randomly to groups (in a crossover study, subjects were allocated randomly in the order in which treatments were received). | ||||||||
Allocation was concealed | ||||||||
The groups were similar at baseline regarding the most important prognostic indicators | ||||||||
There was blinding of all subjects | ||||||||
There was blinding of all therapists who administered the therapy | ||||||||
There was blinding of all assessors who measured at least 1 key outcome | ||||||||
Measures of at least 1 key outcome were obtained from more than 85% of the subjects initially allocated to groups | ||||||||
All subjects for whom outcome measures were available received the treatment or control condition as allocated, or, where this was not the case, data for at least 1 key outcome were analyzed by ‘‘intention to treat’’ | ||||||||
The results of between-groups statistical comparisons are reported for at least 1 key outcome | ||||||||
The study provides both point measures and measures of variability for at least 1 key outcome | ||||||||
| Total PEDro scale score | 4 | 10 | 10 | 10 | 5 | 9 | 10 | 7 |
| Fujii et al. | Fujii et al. | Hostler et al. | Jacobson & Bass | Lambert et al. | McEntire et al. | Ryan et al. | Veltmeijer et al. | |
| Eligibility criteria specified (no points) | ||||||||
Subjects were allocated randomly to groups (in a crossover study, subjects were allocated randomly in the order in which treatments were received). | ||||||||
Allocation was concealed | ||||||||
The groups were similar at baseline regarding the most important prognostic indicators | ||||||||
There was blinding of all subjects | ||||||||
There was blinding of all therapists who administered the therapy | ||||||||
There was blinding of all assessors who measured at least 1 key outcome | ||||||||
Measures of at least 1 key outcome were obtained from more than 85% of the subjects initially allocated to groups | X | |||||||
All subjects for whom outcome measures were available received the treatment or control condition as allocated, or, where this was not the case, data for at least 1 key outcome were analyzed by ‘‘intention to treat’’ | ||||||||
The results of between-groups statistical comparisons are reported for at least 1 key outcome | ||||||||
The study provides both point measures and measures of variability for at least 1 key outcome | ||||||||
| Total PEDro scale score | 4 | 5 | 9 | 3 | 9 | 9 | 6 | 6 |
X = article did not meet criteria, = article met criteria.
Results from included articles on NSAIDs and Tc during exercise.
| Bruning et al. | de Meersman | Hostler et al. | Lambert et al. | McEntire et al. | |
|---|---|---|---|---|---|
| Participants | N = 14 Males and females Age = 55 ± 1 years V̇O2peak = 29.5 ± 1.7 mL/kg/min | N = 8 Males Age 21–34 years Baseline V̇O2max not reported | N = 102 Male and female firefighters Age = 31.9 ± 9.1 years V̇O2max = 44.6 ± 7.2 mL/kg/min | N = 17 Males and females Age = 27 ± 1 years V̇O2max = 62.2 ± 2.1 mL/kg/min | N = 15 Male firefighters Age = 30.5 ± 9.3 years V̇O2max = 46.6 ± 7.0 mL/kg/min |
| NSAID | Aspirin | Aspirin | Aspirin | Aspirin | Aspirin |
| Dose | 81 mg 1 x day for 7–10 days | 500 mg 6 x day for 1 day | 81 mg/day for 14 days | 325 mg 4 x day for 1 day | 81 mg/day for 14 days |
| Timing | Morning of trial | Last dose not reported; mean drug concentration = 17 ± 8 mg/100 mL | Morning of trial | Morning of trial | Last dose not reported |
| Exercise | 120 min recumbent cycle at 60% V̇O2peak | 60 min run at 50% V̇O2max | 50 min intermittent walking at 4.5 km/h with 2.5% incline and 2.5 km/h with 0% incline | 60 min run at 70% V̇O2max | 45 min walk at 6.4 km/h |
| Environment | 30 °C dry/22 °C wet bulb, 40% RH | 18 ± 0.5 °C, 43 ± 2% RH | 38.9 ± 1.1 °C, 19.8 ± 3.8% RH | 22.4 °C, 48% RH | 38.8 ± 2.1 °C, 24.9 ± 9.1% RH |
| Tc Measure | Esophageal | Rectal | Ingestible thermistor | Rectal | Ingestible thermistor |
| Tc Results | NSAID range ≈37.1–38.2 °C, significantly higher than control range ≈36.6–37.9 °C, p < .001 | At 60 min NSAID = 38.2 ± 0.52 °C and control = 37.9 ± 0.56 °C | Range ≈36.7–39.4 °C | Mean = 38.4 ± 0.1 °C | At 45 min NSAID = 39.0 ± 0.7 °C and control = 39.1 ± 0.6 °C |
Abbreviations: RH = relative humidity; Tc = core temperature; V̇O2max = maximal oxygen consumption; V̇O2peak = peak oxygen consumption.
Timing refers to when the last NSAID dose was taken prior to exercise.